David Urech, Numab CEO
Aiming to spur the immune responses that checkpoint inhibitors can't, Swiss biotech Numab earns fresh round of cash
Swiss antibody player Numab saw its last raise come in at just under $24 million, a Series B that closed in March 2020. But …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
